SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Metabolic / GLP-1Research peptide

Tirzepatide

aka Mounjaro · Zepbound

Dual GIP and GLP-1 receptor agonist with stronger weight-loss effects than GLP-1 alone.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Tirzepatide is a synthetic peptide engineered to bind both the GIP and GLP-1 receptors with an extended half-life suitable for weekly dosing.

Source
  • Recombinant and chemical synthesis
Forms
  • Once-weekly subcutaneous injection

Mechanism of action

Co-activates GIP and GLP-1 receptors, producing additive insulinotropic, satiety, and adipose-tissue effects greater than GLP-1 alone.

Pathways
  • · GLP-1 receptor agonism
  • · GIP receptor agonism
  • · Hypothalamic satiety signaling
Receptors
  • · GLP-1 receptor
  • · GIP receptor
Hormones
  • · Insulin
  • · Glucagon

How it acts on the body

Tirzepatide leverages the fact that GIP and GLP-1 are co-secreted by the gut after meals and act on partially overlapping circuits. Activating both receptors produces a larger insulinotropic response, greater appetite reduction, and favorable effects on adipose-tissue energy partitioning that GLP-1 alone does not fully replicate.

Clinically this translates to larger weight loss and A1c reduction than semaglutide at comparable tolerability. Gastrointestinal side effects remain the dominant issue, particularly during dose escalation.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

InsulinIncreases
Glucose-dependent secretion amplified via dual receptor activation.
GlucagonDecreases
Postprandial suppression.
GIP signalingIncreases
Direct receptor agonism beyond what GLP-1 monotherapy provides.
Leptin sensitivityModulates
Improves with weight loss and GIP-mediated adipose effects.

Effects on the body

Decreases
Appetite and body weight
Increases
Insulin secretion (glucose-dependent)
Optimizes
Adipose energy partitioning

Organ system effects

Endocrine

Glucose-dependent insulin and glucagon control.

Brain & CNS

Strong central satiety signaling.

Digestive / Gut

Slowed gastric emptying.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Largest documented weight loss for an injectable peptide therapy
  • Strong A1c improvements
  • Cardiometabolic benefits

Potential side effects

Common
  • · Nausea
  • · Diarrhea
  • · Constipation
  • · Decreased appetite
Rare
  • · Gallstones
  • · Injection-site reactions
Serious
  • · Pancreatitis (rare)
  • · Thyroid C-cell tumor risk (rodent data)

Drug interactions

Insulin or sulfonylureas
Hypoglycemia risk; dose adjustment expected.
moderate
Oral contraceptives
Slowed gastric emptying can reduce absorption.
moderate

Pairing context

Often combined with
  • Resistance training and high protein
    Preserves lean mass during weight loss.
Avoid combining with
  • Personal or family history of MTC or MEN2
    Boxed contraindication shared with GLP-1 class.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.